IL-12β1 deficiency is characterized by selective susceptibility to weakly virulent organisms, including Mycobacterium bovis BCG, non-tuberculous environmental mycobacteria and non-typhoidal salmonellosis. We report here on three cases of Bacille Calmette-Gurin (BCG) disease and one case of disseminated tuberculosis (TB) in two pairs of Chinese siblings with IL-12Rβ1 deficiency.
Family 1 (F1)
P1 was the second child of non-consanguineous parents. Her elder brother (P2), who had not been vaccinated against BCG, died of disseminated TB at 6 years of age. After routine BCG vaccination, P1 developed a tender, progressively enlarged left axillary mass at 1.5 months of age, which subsequently developed to involve the left cervical lymph nodes. Pus aspirated from the infected lymph nodes showed copious amounts of acid-fast bacilli. Response to standard anti-mycobacterial therapy was suboptimal, with persistent ulceration and purulent discharge from the infected lymph nodes. At 23 months of age, the patient died of refractory disseminated BCG and fulminant hepatic failure related to anti-mycobacterial drugs.
Family 2 (F2)
P3 was the second child of non-consanguineous parents. Her brother (P4) died of disseminated BCG at 1 year of age and because of this, BCG vaccination was withheld in P3. At the age of 2 months, lymphocyte subsets and immunoglobulin pattern were normal and BCG was given to P3. Three months later, she presented with left axillary lymph node enlargement and discharge. She was treated with standard anti-mycobacterial drugs which brought her disease under control.
Diagnosis of IL12RB1 mutation
P1 had a novel nonsense mutation 853C>T (Q285X) in exon 9. P3 had a known splice-site mutation 1791+2T>G. (Fig. 1) . Both P2 and P4 died before genetic confirmation could be made. In both cases, the parents were heterozygous for the respective mutant allele and wild-type allele. lymphadenopathy or disseminated BCG. In those without BCG disease, a known history of BCG vaccination was present in 14 patients [2, 5, [7] [8] [9] . If we take our index patients and their siblings into account, the percentage of BCG disease in BCG-vaccinated, IL-12Rβ1-deficient individuals is 71.4% (35 out of 49). The mortality attributable to disseminated BCG is 6/35 (17.1%).
P2 of Family 1, who did not have a history of BCG vaccination, died of disseminated TB. To date, only four IL-12Rβ1-deficient patients have been identified to have culture-proven M. tuberculosis infections -one from Morocco [3] , one from Turkey [6] and a pair of siblings from Spain [4] . The majority of the reported IL-12Rβ1-deficient patients without a history of TB originated from European countries where the incidence of TB was low (3.9-13/100,000 population) compared with than that in Spain (25/100,000), Turkey (28/100,000) and Morocco (110/100,000) [10] . Therefore, the apparently low incidence among IL-12Rβ1-deficient individuals could be directly linked to the chance of exposure [1] , and IL12Rβ1 deficiency may simply not be recognized in patients who have severe TB as the sole presentation. Given the endemicity of TB in China (incidence:101/100,000) [10] , it is possible that children with severe forms of TB may remain undiagnosed of defects in the IL-12-IFN-γ axis.
In view of the family history of disseminated BCG disease following vaccination (P4), we carried out a basic immune workup before BCG vaccination in P3; the results were unrevealing. The diagnosis of IL-12RB1 deficiency was made only after she presented with BCG lymphadenopathy, at which time the IL-12-IFN-γ axis was investigated. As a routine immunological workup is normal, patients with defects of the IL-12-IFN-γ axis can be identified only if such a diagnosis is contemplated. Clinicians should be alerted by a family history of an adverse BCG reaction, and a detailed clinical investigation may be required before BCG vaccination can be safely given. 
